Enteric tilmicosin sustained-release microcapsule and preparation method thereof
The present technology discloses an enteric tilmicosin sustained-release microcapsule and a preparation method thereof, and belongs to the field of tilmicosin preparations. The enteric tilmicosin sustained release microcapsule is made of 10 to 50 wt% of tilmicosin powder, 40 to 88 wt% of fat powder adjuvant and 2 to 10 wt% of an enteric coating material; the enteric coating The material is one or more of fiber vinegar ester, hypromellose phthalate, acrylic resin L type, acrylic resin S type, polyvinyl acetate phthalate, hypromellose acetate succinate The prepared microcapsules have a diameter of 50 to 200 μm; the preparation method comprises the following steps: coating the tilmicosin raw powder and the auxiliary materials in a sub-coating, and coating the material with the enteric coating material for the second time, and drying to obtain the finished product. The patented technology of the invention achieves the purpose of sustained release, prolongs the action time of tilmicosin, and improves the fluidity and dispersibility of the drug, significantly improves the drug effect, and reduces the amount of drug added.
The present technology belongs to the field of tilmicosin preparations, and particularly relates to an enteric tilmicosin sustained-release microcapsule and a preparation method thereof.
Technical introduction tilmicosin is a broad-spectrum antibiotic for macrolides for livestock and poultry. It is mainly used for the prevention and treatment of animal pneumonia, avian mycoplasmosis and mastitis in lactating animals. It has been widely used in animal husbandry. At present, the dosage forms contained in the national standards are premixes, soluble powders, solutions and injections. The tilapia star tastes extremely bitter and has poor palatability. It is irritating to the gastric mucosa and affects the feed intake of the animal body. At the same time, the general tilmicosin premix and powder have poor fluidity and low dispersibility. It is not easy to mix when the material is administered. At present, the domestic tilmicosin preparation forms mainly include the following types: 1. Ordinary powder: directly mix tilmicosin with the auxiliary materials, the process is extremely simple, but because of the difference between the feed granules and the feed granules, it is difficult for the two. Evenly mixed, in addition, the taste is extremely bitter, poor palatability, unstable in the stomach, easy to degrade and irritating to the gastric mucosa. 2. Ordinary granules: The tilmicosin powder and the auxiliary materials are simply mixed to prepare granules with suitable particle size to improve the mixing effect of the tilmicosin preparation and the feed. However, like ordinary powders, the taste is extremely bitter, affecting animal feeding, completely dissolved in gastric acid, no sustained release function and poor antibacterial growth promoting effect.
In view of this, the purpose of the patented technology is to propose an enteric tilmicosin sustained-release microcapsule according to the biological characteristics of tilmicosin, to improve the palatability of tilmicosin, completely masking the strong The bitterness does not affect the feed intake of pigs, and improves the fluidity and dispersibility of the drug, significantly improving the efficacy and reducing the amount of drug added. Another object of the patented technology is to provide a method for preparing enteric tilmicosin sustained-release microcapsules, which is simple and easy to manufacture, and has low production cost. In order to solve the above technical problems, the technical solution adopted by the patented technology is: an enteric tilmicosin sustained release microcapsule, which comprises 10 to 50 wt% of tilmicosin powder, 40 to 88 wt% of fat powder excipients and 2 to 10% by weight of an enteric coating material; the enteric coating material is fiber vinegar ester (CAP), hypromellose phthalate...
[Technical Protection Point]
An enteric tilmicosin sustained-release microcapsule characterized by being composed of 10 to 50% by weight of tilmicosin powder, 40 to 88% by weight of fat powder adjuvant and 2 to 10% by weight of enteric coating material The enteric coating material is fiber vinegar ester, hypromellose phthalate, acrylic resin L type, acrylic resin S type, polyvinyl acetate phthalate, hypromellose acetate succinic acid One or more of the esters; the microcapsules are made to have a diameter of 50 to 200 μm.
[Technical Features Summary]
An enteric tilmicosin sustained-release microcapsule characterized by comprising 10 to 50% by weight of tilmicosin powder, 40 to 88% by weight of fat powder adjuvant and 2 to 10% by weight of enteric coating material The enteric coating material is fiber vinegar ester, hypromellose phthalate, acrylic resin L type, acrylic resin S type, polyvinyl acetate phthalate, hypromellose acetate One or several of succinates; the microcapsules are made to have a diameter of 50-200 μm. The enteric tilmicosin sustained-release microcapsule according to claim 1, wherein the fat powder is made of soybean oil, fish oil, lecithin, expanded corn, vitamin E and an antioxidant. The enteric tilmicosin sustained-release microcapsule according to claim 2, wherein the fat powder comprises 20-40% by weight of soybean oil, 20-40% by weight of fish oil, and 20-40% by weight of lecithin. , 10-20w...
household medical devices, are especially designed for the chocking rescuing and medical care at home
Chocking rescue device, medical device, PVC masks, first aid
2 MEDS TECHONOLOGY CO.,LTD , https://www.2-meds.com